Participated · Debt Financing · Jul 2025

Insomnia Labs built CreatorFi to provide stablecoin-based and fiat lending that lets creators borrow against future earnings such as YouTube ad revenue and music royalties. The platform integrates real-time, AI-powered underwriting and embedded payments directly into existing creator platforms, enabling fast, flexible advances and instant conversion of stablecoin advances into local currencies via Coinbase Offramp. CreatorFi is built on Avalanche for secure, transparent, and scalable tokenization of creator income and uses the Coinbase Developer Platform to manage stablecoin liquidity and disbursements. Early adoption includes Yoola (a YouTube Multi-Channel Network with over 1,200 creators) and Record (a royalty infrastructure platform) leveraging the product for enterprise clients. Insomnia has secured an initial $12 million credit facility and a $5 million bond program tied to Yoola, with additional backing from real-world-asset investors. The company positions CreatorFi to scale as demand grows amid a creator-economy market projected to reach $1.49 trillion by 2034. Insomnia Labs, formerly Luna Market, is a NYC-based Web3 advertising and technology company focused on bringing brands into the metaverse. Led by Billy Huang and Jack Cameron, the firm uses proprietary in-house technologies to launch fully digital, scalable campaigns and to deploy advertising and technology services. Its core capabilities include NFTs, DAOs, metaverse activations, web3-native strategy, creative, data, and measurement. Clients include Under Armour, L’Oreal, WPP and Curry Brands; its work with Curry Brands and Under Armour involved large NFT campaigns and the launch of basketball-inspired NF3s linked to Stephen’s on-court performance during the NBA playoffs. Now operating as Insomnia Labs, the company is expanding its offerings to provide a full suite of advertising and technology services to help brands achieve their metaverse goals. The company raised USD 1.5M in the reported funding round.

Led · Series A · Feb 2023

Nalu Bio is a biotech company creating chemistry-based cannabinoids for the consumer and pharmaceutical markets. Its platform generates molecularly identical versions of naturally occurring cannabinoids (CBD, THCV, CBN, CBC, CBG) that are sustainable and free from contaminants found in hemp-extracted cannabinoids. The company intends to use recent funding to accelerate growth and scale production of cannabinoids for consumer products and therapeutics. Nalu Bio was founded in 2019 and is led by CEO Caitlyn Krebs. It is headquartered in San Francisco, CA. The company's technology targets both consumer product and therapeutic applications. Nalu Bio develops next-generation cannabinoid ingredients via a chemistry-based proprietary synthesis platform that produces ultra-pure, consistently performing cannabinoids without contamination risks associated with hemp extraction. The platform is scalable and designed to meet anticipated market expansion, supplying global retail and pharmaceutical markets. The company emphasizes research- and evidence-based cannabinoids and operates with a team of chemists and scientists focused on transparency and quality. Nalu Bio positions its products as free from THC, heavy metals, and pesticides, aiming for wide accessibility and high quality. Leadership highlights a commitment to rigorous standards when partnering with investors and scaling operations.

Led · Series A · Oct 2022

Biopharmaceutical Research Company (BRC) is a DEA-registered botanical cannabis firm focused on the federally compliant production of active pharmaceutical ingredients and partnered development and research. Led by CEO George Hodgin and based in Monterey, CA, the company holds an active Drug Enforcement Administration pharmaceutical cannabis license. BRC has engaged in partnered research with academic institutions including Washington State University and the University of California–Davis. The company raised $20M in a Series A to support its growth. BRC plans to use the funds to scale up operations, increase its product offering, conduct sponsored research, and execute its go-to-market strategy.

Led · Equity · Feb 2022

NextEvo Naturals is a premium supplement brand that launched a proprietary delivery technology and an evidence-backed line of cannabidiol (CBD) products. Its SmartSorb™ technology creates a water-dispersible emulsion that the company says delivers the equivalent of four times the CBD versus oil-based formulations and enables rapid absorption. NextEvo cites evidence-based scientific trials demonstrating SmartSorb’s superiority and plans to conduct additional trials this year. The company’s research team includes medical and scientific professionals with over 100 years of combined experience at organizations such as Johnson & Johnson and GlaxoSmithKline. Initial products include 10 mg and 15 mg THC-free high-absorption CBD capsules (the 15 mg is also available as a mint chewable) and a Triple Action Sleep capsule combining 5 mg CBD with immediate and controlled-release melatonin. All products are manufactured in an FDA-inspected, GMP-certified facility and are independently tested by an ISO/IEC-accredited third-party testing facility. NextEvo used proceeds from a $15 million investment round to support pre-launch development and commercialization of its initial product line.

Participated · Equity · Sep 2021

Hound Labs develops a patented, ultra-sensitive portable breath-testing technology whose first commercial product is the HOUND® Marijuana Breathalyzer that measures THC in breath to identify recent cannabis use. The device targets THC in breath, where the molecule remains for only a few hours, allowing employers and law enforcement to distinguish recent use from earlier consumption detected by urine, hair, or oral-fluid tests. The company says its technology better aligns detection windows with impairment and can be used on-site for rapid screening. Hound Labs is preparing to scale production and is negotiating multi‑million‑dollar contracts ahead of a planned commercial launch in 1Q22. Company leadership has highlighted future applications of the platform, including detecting pathogens such as SARS‑CoV‑2 or disease biomarkers by changing the targeted compound. The company was founded in 2014 and is headquartered in Oakland, Calif. Hound Labs is a breath-technology company that has developed ultra-sensitive technology for non-invasive breath measurement. Using that technology, the Hound® marijuana breathalyzer rapidly, accurately and inexpensively measures recent marijuana use and alcohol in breath. The breathalyzer is intended for law enforcement, employer and insurance purposes. The company was founded in 2014 by Dr. Mike Lynn, who serves as CEO and co-founder, and is based in Oakland, CA. Hound Labs closed a $30M Series D financing to accelerate manufacturing and commercial availability. The round was led by Intrinsic Capital Partners and included participation from NFP Ventures, Main Street Advisors, Icon Ventures and Benchmark. Hound Labs develops a patent-pending marijuana breathalyzer that measures recent THC in breath to indicate current impairment. The device achieves parts‑per‑trillion sensitivity for THC molecules, unlike alcohol breathalyzers that detect alcohol at parts‑per‑thousand. Led by CEO Dr. Mike Lynn, the company positions the breathalyzer as an essential tool for law enforcement and employers. Hound Labs raised $8.1M in venture capital from Benchmark and will use the funds to support clinical trials, field studies and a move toward manufacturing. The first clinical trials began at San Francisco General Hospital under Kara Lynch, PhD, and the company plans additional field studies with law enforcement in multiple U.S. cities. Hound Labs intends to begin manufacturing in the fourth quarter of 2017.